*僅供醫(yī)學(xué)專(zhuān)業(yè)人士閱讀參考

自1995年NINDS研究問(wèn)世以來(lái)，靜脈溶栓治療已成為急性缺血性卒中（AIS）再灌注治療最主要的手段。其中阿替普酶為主要的溶栓藥物，顯著改善了AIS患者的預(yù)后[1]。替奈普酶作為一種新型纖溶酶原激活物，因其獨(dú)特的藥理學(xué)特性及操作簡(jiǎn)便性，近年來(lái)已成為再灌注治療領(lǐng)域的研究熱點(diǎn)，已被視為AIS患者溶栓治療的新標(biāo)準(zhǔn)。

*以下內(nèi)容僅供在中國(guó)大陸執(zhí)業(yè)的

醫(yī)療衛(wèi)生專(zhuān)業(yè)人士瀏覽。

參考文獻(xiàn)：

[1]董漪,董強(qiáng).中國(guó)卒中臨床研究中的溶栓治療：20年的成就與發(fā)展方向[J].中國(guó)卒中雜志,2025,20(05):549-554.

[2]國(guó)家衛(wèi)生健康委加強(qiáng)腦卒中防治工作減少百萬(wàn)新發(fā)殘疾工程專(zhuān)家委員會(huì),吉訓(xùn)明. 《2024年中國(guó)腦卒中防治報(bào)告》概要[J]. 首都醫(yī)科大學(xué)學(xué)報(bào),2025.

[3]王擁軍,李子孝,谷鴻秋,等.中國(guó)卒中報(bào)告2020（中文版）(1)[J].中國(guó)卒中雜志,2022,17(05):433-447.

[4]Wang J, Xiao C, Cheng Z, et al. Analysis and prediction of disease burden of stroke and its subtypes in China from 1990 to 2040. Chin Med J (Engl). 2025 Aug 27;138(19):2452–63.

[5]Heeley E, Anderson CS, Huang Y, et al. Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke. 2009 Jun;40(6):2149-56.

[6]Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011 Jun;42(6):1658-64.

[7]中華醫(yī)學(xué)會(huì)神經(jīng)病學(xué)分會(huì),中華醫(yī)學(xué)會(huì)神經(jīng)病學(xué)分會(huì)腦血管病學(xué)組. 中國(guó)急性缺血性卒中診治指南2023[J]. 中華神經(jīng)科雜志,2024,57(06)：523-559.

[8]Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3670-4.

[9]Zhu A, Rajendram P, Tseng E,et al. Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review. Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795.

[10]Tanswell P, Modi N, Combs D,et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229-45.

[11]Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022 Jul 16;400(10347):161-169.

[12]Muir KW, Ford GA, Ford I, et al. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol. 2024 Nov;23(11):1087-1096.

[13]Parsons MW, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024 Aug;23(8):775-786.

[14]Palaiodimou L, Katsanos AH, Turc G,et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. Neurology. 2024 Nov 12;103(9):e209903.

[15]Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024 Nov 5;332(17):1437-1445.

[16]熊云云,等.卒中:回眸2024[J].中國(guó)卒中雜志,2025,20(1):1-19.

[17]Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418.

[18]Alamowitch S, Turc G, Palaiodimou L,et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023 Mar;8(1):8-54.

[19]中國(guó)卒中學(xué)會(huì), 《中國(guó)卒中學(xué)會(huì)急性缺血性卒中再灌注治療指南》編寫(xiě)組, 王擁軍. 中國(guó)卒中學(xué)會(huì)急性缺血性卒中再灌注治療指南2024.中國(guó)卒中雜志,2024,19(12):1460-1478.

[20]Sk?rlund M, ?sberg S, Eriksson M, et al. Tenecteplase compared to alteplase in real-world outcome: A Swedish Stroke Register study. Ups J Med Sci. 2024 Oct 9;129.

[21]Warach SJ, Dula AN, Milling TJ, et al. Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. Stroke. 2022 Dec;53(12):3583-3593.

[22]Gao L, Moodie M, Mitchell PJ, et al. Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke. Stroke. 2020 Dec;51(12):3681-3689.

[23]原研替奈普酶說(shuō)明書(shū).

審批號(hào)：SC-CN-18259，有效期至2026年12月1日

*"醫(yī)學(xué)界"力求所發(fā)表內(nèi)容專(zhuān)業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。